BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif ...
BioTime and its subsidiaries are leveraging their industry-leading experience in pluripotent stem cell technology and a broad intellectual property portfolio to facilitate the development and use of ...
Alameda-based BioTime, which has seen its stock double in the past year, reached an agreement this week to provide important embryonic stem cell lines to California-based researchers for free in hopes ...
* Biotime Inc files for possible resale of up to 4.92 million shares of co's common stock, no par value per share, by selling shareholders - sec filing Source text for Eikon: Further company coverage: ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a ...
BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Con
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive ...
BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Con
BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback